Related Experiment Video
Updated: Feb 9, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Ewa Gogola1, Alexandra A Duarte1, Julian R de Ruiter2
1Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
Abstract:
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the treatment of homologous recombination (HR)-deficient cancers. Despite the success of this approach, drug resistance is a clinical hurdle, and we poorly understand how cancer cells escape the deadly effects of PARPi without restoring the HR pathway. By combining genetic screens with multi-omics analysis of matched PARPi-sensitive and -resistant Brca2-mutated mouse mammary tumors, we identified loss of PAR glycohydrolase (PARG) as a major resistance mechanism. We also found the presence of PARG-negative clones in a subset of human serous ovarian and triple-negative breast cancers. PARG depletion restores PAR formation and partially rescues PARP1 signaling. Importantly, PARG inactivation exposes vulnerabilities that can be exploited therapeutically.
Insights
Loss of PAR glycohydrolase (PARG) confers resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in homologous recombination-deficient cancers. PARG inactivation reveals new therapeutic vulnerabilities in ovarian and breast cancers.
Area of Science:
- Oncology
- Cancer Biology
- Genetics
Background:
- Poly(ADP-ribose) polymerase inhibitors (PARPi) are effective against homologous recombination (HR)-deficient cancers.
- Drug resistance to PARPi is a significant clinical challenge.
- Mechanisms of PARPi resistance independent of HR restoration are poorly understood.
Purpose of the Study:
- To identify novel mechanisms of PARPi resistance in HR-deficient cancers.
- To investigate the role of PAR glycohydrolase (PARG) in PARPi resistance.
- To explore therapeutic vulnerabilities associated with PARG inactivation.
Main Methods:
- Genetic screens in Brca2-mutated mouse mammary tumors.
- Multi-omics analysis of PARPi-sensitive and -resistant tumors.
- Analysis of human serous ovarian and triple-negative breast cancer samples.
Main Results:
- Loss of PAR glycohydrolase (PARG) was identified as a major PARPi resistance mechanism.
- PARG-negative clones were found in human ovarian and breast cancers.
- PARG depletion partially restored poly(ADP-ribose) (PAR) formation and PARP1 signaling.
Conclusions:
- PARG inactivation is a key driver of PARPi resistance in HR-deficient cancers.
- PARG-negative cancer cells exhibit vulnerabilities exploitable for therapy.
- Targeting PARG may offer new therapeutic strategies for resistant cancers.
Related Concept Videos
Restorative Care
Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Line Loss
Line loss impacts power delivery efficiency in a balanced three-phase circuit. The symmetry in such a circuit simplifies the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...

